Skip to content
DataLookout
Menu

POSALLONCT06541067

Study of Posaconazole Prophylaxis in Patients Receiving Hematopoietic Stem Cell Allograft (Allo-HSC) at High Risk of Invasive Fungal Infection (IFI)

StatusRecruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 28 words Show 5 more changesShow less
    • Primary completion date changed from estimate of Jan 15, 2027 to Sep 9, 2026
    • Study completion moved earlier from Nov 8, 2028 to Jun 2027
    • Secondary endpoints: details revised at 12 of 17 entries
    • Study description revised
    • Site details revised
  2. Study Identification, Study Status, Oversightv3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study completion date: Oct 15, 2028 to Nov 8, 2028
    • Start date changed from estimate of Oct 15, 2024 to Nov 8, 2024
    • Site details revised
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Effective residual concentration of posaconazole
Timeframe: On the 8th day of treatment (i.e. after 7 days of treatment)

Secondary (14)

Monitoring of residual plasma concentrations [C]min
Description of circumstances leading to posaconazole underdosing
Description of the reasons for administering posaconazole intravenously (IV)
Description of situations leading to initial non-administration or early discontinuation of posaconazole
Description of invasive fungal infections occurring
Show 9 moreShow less
Description of patient outcome: incidence of engraftment
Description of patient outcome: overall survival (OS)
Description of patient outcome: disease-free survival (DFS)
Description of patient outcome: non-relapse mortality (NRM)
Description of patient outcome: incidence of relapse (IR)
Description of patient outcome: cumulative incidence of acute GVHD
Description of patient outcome: cumulative incidence of chronic GVHD
Description of patient outcome: GVHD-free relapse-free survival (GRFS)
Grade 3 and 4 post-transplant adverse events

Arms and interventions

PosaconazoleExperimental

Drugs: Posaconazole

Sites

1 site in 1 country

  • CHU NantesNantes, France